Back to results
US 2018/0000829 A1Published application
Emulsion formulations of aprepitant
AssigneeHeron Therapeutics, Inc.
InventorsThomas B. Ottoboni, Han Han
Life of this patent
Estimating the term…
Abstract
Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Claims21
A physically stable pharmaceutical composition comprising:
- 0.4 wt/wt % to 1.0 wt/wt % aprepitant;
- 13 wt/wt % to 15 wt/wt % egg yolk lecithin;
- 9 wt/wt % to 10 wt/wt % soybean oil;
- and
- a pH modifier, wherein the pH modifier is sodium oleate;
- wherein the pH of the composition ranges from 7.5 to 9.0,
- wherein the ratio of egg yolk lecithin to aprepitant (wt %:wt %) ranges from about 18:1 to 22:1.
4 more elements
A physically stable pharmaceutical composition suitable for intravenous administration comprising:
- 0.7 wt/wt % aprepitant;
- 14 wt/wt % egg yolk lecithin;
- 9 wt/wt % to 10 wt/wt % soybean oil;
- and
- a pH modifier, wherein the pH modifier is sodium oleate;
- wherein the pH of the composition ranges from 7.5 to 9.0,
- wherein the ratio of egg yolk lecithin to aprepitant (wt %:wt %) ranges from about 18:1 to 22:1.
4 more elements
Dependencies are inferred from the claim text.